UC WAR. CALL 09/24 GS71/ DE000HC9M360 /
5/16/2024 9:46:47 PM | Chg.-0.1900 | Bid9:59:02 PM | Ask9:59:02 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.6300EUR | -4.97% | 3.5400 Bid Size: 1,000 |
3.6600 Ask Size: 1,000 |
Gsk PLC ORD 31 1/4P | 15.00 - | 9/18/2024 | Call |
GlobeNewswire
5/16
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire
5/15
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/9
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/9
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...
GlobeNewswire
5/9
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...
GlobeNewswire
5/9
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/9
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
GlobeNewswire
5/9
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
5/8
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/8
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...
GlobeNewswire
5/8
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...
GlobeNewswire
5/7
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Roun...
GlobeNewswire
5/1
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4/30
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the Euro...
GlobeNewswire
4/30
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial o...
GlobeNewswire
4/25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...